Inmune Bio (INMB) Retained Earnings (2017 - 2025)
Inmune Bio (INMB) has disclosed Retained Earnings for 9 consecutive years, with -$209.0 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 36254.26% to -$209.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$209.0 million through Dec 2025, down 36254.26% year-over-year, with the annual reading at -$209.0 million for FY2025, 36254.26% down from the prior year.
- Retained Earnings hit -$209.0 million in Q4 2025 for Inmune Bio, down from -$764000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $56000.0 in Q1 2022 to a low of -$209.0 million in Q4 2025.
- Historically, Retained Earnings has averaged -$30.4 million across 5 years, with a median of -$710000.0 in 2023.
- Biggest YoY gain for Retained Earnings was 100.15% in 2022; the steepest drop was 70000.0% in 2022.
- Year by year, Retained Earnings stood at $1000.0 in 2021, then plummeted by 70000.0% to -$699000.0 in 2022, then fell by 14.31% to -$799000.0 in 2023, then grew by 28.04% to -$575000.0 in 2024, then tumbled by 36254.26% to -$209.0 million in 2025.
- Business Quant data shows Retained Earnings for INMB at -$209.0 million in Q4 2025, -$764000.0 in Q3 2025, and -$197.3 million in Q2 2025.